ArticleNature communications2022
Host lung microbiota promotes malaria-associated acute respiratory distress syndrome.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Gut Bacteroides act in a microbial consortium to cause susceptibility to severe malaria.Nature communications · 2023Pooled it
- Beyond the mouse: organoids, spheroids, and organs-on-chips as the (inevitable) future of malaria research?Malaria journal · 2026Review
- Gut microbiota bidirectionally influences protection and severity in cerebral malaria in mice.Tropical medicine and health · 2026Article
- Differential Effects of DHA-Rich Fish Oil Supplementation on Intestinal and Pulmonary Alterations in Experimental Malaria Caused byACS omega · 2026Article
- Leveraging microphysiological systems to expedite understanding of host-parasite interactions.PLoS pathogens · 2025Review
- Serum Proteomics of Experimental Malaria-Associated ARDS Reveals a Regulation of Acute-Phase Response Proteins.Journal of immunology research · 2025Article
- Lung microbiota: a new hope for treating acute respiratory distress syndrome?Frontiers in microbiology · 2025Review
- The microbiota, the malarial parasite, and the mice-a three-sided relationship.Frontiers in microbiology · 2025Review
- Monitoring of deep lymphocyte phenotypes in the blood and bronchoalveolar lavage fluid of patients with severe malaria-associated acute respiratory distress syndrome.Critical care science · 2025Article
- Unlocking the potential for microbiome-based therapeutics to address the sustainable development goal of good health and wellbeing.Microbial biotechnology · 2024Review
- Blockage of mechanosensitive Piezo1 channel alleviates the severity of experimental malaria-associated acute lung injury.Parasites & vectors · 2024Article
- PRL2 regulates neutrophil extracellular trap formation which contributes to severe malaria and acute lung injury.Nature communications · 2024Article
- Applicability of Redirecting Artemisinins for New Targets.Global challenges (Hoboken, NJ) · 2023Review
- Malaria Genomics, Vaccine Development, and Microbiome.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 4 countries.
Funding
Abstract
Severe malaria can manifest itself with a variety of well-recognized clinical phenotypes that are highly predictive of death - severe anaemia, coma (cerebral malaria), multiple organ failure, and respiratory distress. The reasons why an infected individual develops one pathology rather than another remain poorly understood. Here we use distinct rodent models of infection to show that the host microbiota is a contributing factor for the development of respiratory distress syndrome and host mortality in the context of malaria infections (malaria-associated acute respiratory distress syndrome, MA-ARDS). We show that parasite sequestration in the lung results in sustained immune activation. Subsequent production of the anti-inflammatory cytokine IL-10 by T cells compromises microbial control, leading to severe lung disease. Notably, bacterial clearance with linezolid, an antibiotic commonly used in the clinical setting to control lung-associated bacterial infections, prevents MA-ARDS-associated lethality. Thus, we propose that the host's anti-inflammatory response to limit tissue damage can result in loss of microbial control, which promotes MA-ARDS. This must be considered when intervening against life-threatening respiratory complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.